Clinical Guides
Multiple Myeloma
A clinically focused clinical guide to recognising, confirming and managing multiple myeloma in India, with explicit emergency, renal, skeletal, treatment and evidence-jurisdiction safeguards.
MedNext Academy | 13 min read
Multiple Myeloma
A clinically focused clinical guide to recognising, confirming and managing multiple myeloma in India, with explicit emergency, renal, skeletal, treatment and evidence-jurisdiction safeguards.
Summary
Multiple myeloma is a clonal plasma-cell malignancy characterised by marrow infiltration and production of a monoclonal immunoglobulin, immunoglobulin fragment or, less commonly, no readily measurable secreted protein. Disease effects arise from tumour burden and the monoclonal product: anaemia, renal injury, hypercalcaemia, osteolytic bone disease, recurrent infection, hyperviscosity, neuropathy and amyloid-associated organ dysfunction. The older CRAB mnemonic remains useful, but active myeloma can also be diagnosed before organ damage when a validated myeloma-defining biomarker predicts an imminent high risk of progression. A paraprotein alone is not synonymous with cancer. Monoclonal gammopathy of undetermined significance and smouldering myeloma require risk-stratified surveillance rather than automatic chemotherapy.
Evaluation must join serum and urine monoclonal-protein studies, serum free light chains, marrow morphology and immunophenotype, whole-body skeletal imaging, blood counts, renal and calcium assessment, and cytogenetic risk. A single normal protein electrophoresis does not exclude light-chain or non-secretory disease. Treatment is specialist-led and depends on frailty, transplant eligibility, cytogenetics, renal function, prior therapies, infection risk and access. It combines anti-myeloma therapy with bone, renal, infection, thrombosis, transfusion and pain care. Suspected spinal cord compression, severe hypercalcaemia, sepsis, rapidly worsening kidney injury or hyperviscosity is an emergency. This quarantined educational draft does not prescribe a regimen and has been reviewed by the MedNext Clinical Team before publication.
How Common Is It?
Myeloma is predominantly a disease of older adults, although it can occur earlier. Incidence rises steeply with age, and the median age reported by international registries should not be imported directly into an Indian clinic. India's age distribution, competing mortality, diagnostic access and cancer-registration coverage differ from high-income populations. Population-based cancer registries provide more defensible estimates than tertiary-centre case series, but registry catchments are not a complete national census. Apparent increases can reflect ageing, improved electrophoresis and imaging, referral concentration or better registration as well as a true change in incidence.
Monoclonal gammopathy is more common than myeloma and becomes more frequent with age. Most people with an incidental small monoclonal protein do not have active malignancy at that moment, yet they need correct classification because progression risk is persistent and heterogeneous. Conversely, people with light-chain disease may have marked renal or bone injury without a conspicuous serum M spike. Hospital-based Indian reports may overrepresent advanced presentation, renal failure and skeletal complications because asymptomatic precursor states and patients unable to reach specialist care are missed.
For an individual, prevalence does not decide the diagnosis. Persistent unexplained anaemia, bone pain, fragility fracture, renal dysfunction, hypercalcaemia, recurrent infection, high total protein, rouleaux or a monoclonal result warrants a structured assessment. For service planning, useful measures include turnaround time for immunofixation and free light chains, access to low-dose whole-body CT or equivalent imaging, marrow and fluorescence in-situ hybridisation capacity, dialysis, radiotherapy, blood products and transplant referral rather than a single headline incidence figure.
Risk Factors
Established associations include increasing age, male sex, family history of plasma-cell disorders and a preceding monoclonal gammopathy. Risk varies across ancestry groups in international studies, but ancestry is not a diagnostic test and should never substitute for investigation. Most patients have no modifiable cause that explains why the clone arose. Obesity has been associated with higher risk in observational evidence, while claims that a particular food, occupation or ordinary infection causes myeloma are usually unsupported. Prior ionising radiation or selected occupational exposures may be relevant in an individual history, but causal attribution is difficult and must not delay care or create blame.
The clinically important risk assessment after a monoclonal protein is detected is different from aetiological risk. The type and concentration of protein, involved-to-uninvolved free-light-chain ratio, marrow plasma-cell proportion, imaging findings and evolving laboratory pattern help distinguish precursor states and estimate progression. Active disease risk is also shaped by cytogenetic abnormalities, stage, extramedullary disease, plasma-cell leukaemia features, renal impairment, frailty and treatment response. These variables require specialist interpretation; one adverse result cannot be understood outside the complete dataset.
Treatment introduces additional risks. Immunomodulatory drugs can increase venous thrombosis, proteasome inhibitors may cause neuropathy or viral reactivation, monoclonal antibodies can cause infusion reactions and infection, corticosteroids worsen glucose control and mood, and bone-modifying agents can cause hypocalcaemia, renal toxicity or osteonecrosis of the jaw. Transplant conditioning causes profound cytopenia and infection risk. Medication access, travel, nutrition, caregiver support and reliable monitoring are therefore part of risk assessment in India, not administrative afterthoughts.
Diagnosis
History
Ask about persistent back, rib or long-bone pain; height loss; fracture; fatigue; dyspnoea; recurrent or unusual infection; thirst, constipation, confusion or polyuria suggesting hypercalcaemia; reduced urine output; bleeding; headache or visual disturbance; neuropathy; weight loss and functional decline. Document symptom tempo, analgesic and NSAID exposure, diabetes, kidney disease, prior malignancy, radiotherapy, family history and any known monoclonal result. Specifically ask about orthostatic symptoms, oedema, tongue enlargement, bruising or heart-failure features that may point to AL amyloidosis. Sudden weakness, sensory level or bladder dysfunction suggests cord compression.
Examination
Assess observations, hydration, mental state and sepsis. Look for pallor, bruising, infection, dehydration, oedema and heart failure. Palpate focal skeletal tenderness without forceful percussion; examine gait and spine alignment. Perform a complete neurological examination when pain, weakness or sphincter symptoms are present. Macroglossia, periorbital purpura, autonomic neuropathy or restrictive cardiomyopathy features warrant an amyloid pathway, but their absence does not exclude it.
Investigations
Obtain CBC and film, creatinine with estimated filtration, electrolytes, corrected or ionised calcium, albumin, total protein, liver tests and LDH. Monoclonal studies should include serum electrophoresis and immunofixation, quantitative immunoglobulins, serum free light chains, plus urine protein assessment, electrophoresis and immunofixation as clinically indicated. Confirm clonality and burden through marrow aspirate and trephine with immunophenotyping and cytogenetic/FISH risk testing. Use whole-body low-dose CT, PET-CT or whole-body MRI according to indication and availability; a plain skeletal survey is less sensitive. Apply IMWG criteria: clonal marrow plasma cells or plasmacytoma plus CRAB injury attributable to the clone or a validated SLiM biomarker. Attribution, thresholds and imaging definitions must be checked from the current specialist standard.
Differential Diagnosis
Monoclonal gammopathy of undetermined significance has a monoclonal protein without myeloma-defining events and below specified marrow or protein thresholds. Smouldering myeloma has a greater clonal burden but no attributable defining event. Both require formal classification and follow-up; neither should be relabelled active myeloma simply because a patient has common age-related back pain or chronic kidney disease. Solitary plasmacytoma has a localised plasma-cell tumour without systemic myeloma, while multiple plasmacytomas, marrow disease or additional lesions alter the category.
Other monoclonal-protein disorders include Waldenstrom macroglobulinaemia or lymphoplasmacytic lymphoma, AL amyloidosis, monoclonal gammopathy of renal significance, cryoglobulinaemia, POEMS syndrome and other B-cell neoplasms. Pattern matters: lymphadenopathy, splenomegaly, hyperviscosity, demyelinating neuropathy, nephrotic proteinuria, cardiomyopathy, organomegaly, endocrine disturbance or skin change may redirect the evaluation. A small clone can still cause severe renal, neural or amyloid organ injury, so tumour quantity alone is not reassurance.
Polyclonal hypergammaglobulinaemia from chronic infection, autoimmune disease or liver disease can mimic high globulin but lacks a single clonal pattern. Metastatic bone cancer, lymphoma, osteoporosis, osteomalacia, hyperparathyroidism, vertebral infection and inflammatory disorders can produce pain, fractures or lytic-appearing abnormalities. Anaemia may reflect iron deficiency, chronic inflammation, haemolysis, bleeding or another marrow disorder; kidney injury may be diabetic, hypertensive, obstructive, drug-related or infectious. The diagnosis demands concordance among symptoms, laboratory clonality, marrow and imaging, with tissue review when findings conflict.
Management
Active myeloma requires prompt haematology-oncology care. Before therapy, define performance status and frailty, transplant eligibility, cytogenetic risk, renal function, infection history, neuropathy, thrombosis risk, vaccination status, dental health, fertility priorities and patient goals. Contemporary initial treatment commonly combines agents from different classes, but the correct drugs, doses and sequence change rapidly and vary with approval, affordability, renal function and transplant strategy. This guide deliberately does not name a universal regimen. Eligible patients may proceed after induction to stem-cell collection and autologous transplantation; chronological age alone should not decide eligibility. Older or frail adults need calibrated intensity rather than therapeutic abandonment.
Response is monitored with the marker that was measurable at baseline, alongside blood counts, renal function, calcium, symptoms and selective marrow or imaging. A biochemical change must be interpreted using validated response criteria. Maintenance, relapse treatment and newer immune therapies require updated specialist protocols and prior-exposure review. Shared decisions should cover expected benefit, uncertainty, hospital burden, reproductive issues, financial toxicity and alternatives. Clinical-trial access can be appropriate but must not be presented as guaranteed.
Supportive care is integral. Treat hypercalcaemia and kidney injury urgently, avoid nephrotoxins, maintain safe hydration, address infection promptly and provide thromboprophylaxis when treatment-related risk warrants it. Bone-modifying treatment requires renal, calcium, vitamin D and dental assessment. Pain care may combine systemic analgesia, radiotherapy, bracing, surgery and rehabilitation; unsafe manipulation of lytic bone is avoided. Provide vaccination planning, antiviral or antimicrobial prophylaxis when regimen-specific, transfusion support, nutrition, psychological care and early palliative-care input based on needs, not prognosis alone.
Prescribing Information
Anti-myeloma medicines have narrow, regimen-specific safety requirements and should be prescribed only through an oncology protocol with pharmacy verification. Confirm body size where relevant, kidney and liver function, blood counts, pregnancy potential, interactions, previous toxicities and planned supportive medicines before every cycle. Dexamethasone can cause hyperglycaemia, insomnia, infection, mood change and myopathy; dose reduction is often important in frailty. Immunomodulatory medicines are teratogenic and require formal pregnancy-prevention controls plus thrombosis assessment. Proteasome inhibitors need neuropathy review and, for selected agents, antiviral prophylaxis. Anti-CD38 antibodies affect transfusion compatibility testing, so the transfusion laboratory should be informed before exposure and baseline testing arranged.
Bisphosphonates and denosumab are not interchangeable casual prescriptions. Choice and interval depend on renal function, calcium balance, dental status, disease activity and local protocol. Correct significant hypocalcaemia and arrange dental prevention; jaw pain or a non-healing socket needs review. In acute kidney injury, stop avoidable nephrotoxins and obtain urgent myeloma advice rather than empirically reducing every medicine. NSAIDs can worsen renal perfusion and are generally unsafe when myeloma kidney injury is possible.
Antimicrobial prophylaxis, vaccination timing and immunoglobulin replacement depend on regimen, infection pattern and immune status. Thromboprophylaxis depends on both treatment and patient factors; neither aspirin nor anticoagulation is universally correct. Transfusion orders should account for prior antibodies and anti-CD38 interference. Exact dose, route, cycle, missed-dose action, laboratory thresholds and hold criteria must come from the current institutional protocol. New fever, dyspnoea, confusion, oliguria, bleeding or severe rash during treatment needs urgent assessment rather than advice to wait for the next clinic.
When to Refer
Urgently refer any patient with a confirmed monoclonal protein plus otherwise unexplained anaemia, renal impairment, hypercalcaemia, bone pain, pathological fracture or suspicious imaging. The same urgency applies when serum free light chains are markedly abnormal, even if electrophoresis is inconspicuous. A possible monoclonal gammopathy of renal significance or AL amyloidosis needs coordinated haematology and nephrology, cardiology or neurology evaluation because a small clone can cause irreversible organ damage. Do not wait for all outpatient tests if kidney function is deteriorating or neurological compromise is possible.
Immediate hospital assessment is required for spinal cord or cauda equina symptoms, severe or symptomatic hypercalcaemia, rapidly progressive acute kidney injury, sepsis, major bleeding, symptomatic hyperviscosity, severe anaemia with instability, or impending/pathological fracture that threatens mobility or neurovascular function. Discuss spinal imaging and corticosteroid decisions with the emergency oncology pathway; inappropriate delay or unsupervised steroid use can complicate diagnosis and definitive treatment.
Refer stable incidental paraproteins through a defined pathway that includes full blood count, renal function, calcium, immunoglobulin characterisation and clinical review. The threshold and timing depend on protein type and concentration, free-light-chain ratio, immunoparesis, symptoms and trajectory. Haematology should specify whether the person has MGUS, smouldering myeloma, active disease or another clonal disorder and provide a follow-up plan. Dentistry, renal medicine, orthopaedics, radiation oncology, pain or palliative care, rehabilitation, fertility services and transplant teams should be involved according to need. Cross-specialty ownership must remain explicit so an abnormal result is not lost between services.
Red Flags
New limb weakness, numbness, saddle sensory change, gait collapse or bladder or bowel dysfunction with back pain may indicate spinal cord or cauda equina compression. Keep the spine protected, arrange emergency imaging and involve the specialist pathway immediately. Sudden severe localised bone pain, deformity or inability to bear weight suggests pathological fracture. Headache, confusion, visual change, mucosal bleeding or dyspnoea with a large paraprotein may represent hyperviscosity; urgent specialist assessment is needed and red-cell transfusion decisions should be coordinated because viscosity can worsen.
Myeloma-related kidney injury can progress quickly. Oliguria, rising creatinine, dehydration, vomiting, hypercalcaemia or recent NSAID/contrast exposure needs same-day evaluation, free-light-chain assessment and haematology-nephrology coordination. Do not assume dialysis-dependent injury is irreversible, and do not delay clone-directed therapy while pursuing unproven extracorporeal approaches. Severe thirst, constipation, vomiting, shortened QT interval, confusion or arrhythmia can signal dangerous hypercalcaemia.
Fever, rigors, hypotension, hypoxia or altered consciousness in a treated patient is sepsis until assessed. Neutropenia may blunt local signs. New chest pain or dyspnoea raises infection, anaemia, thromboembolism, cardiac amyloid or treatment toxicity. Bleeding with thrombocytopenia or anticoagulation, acute haemolysis after transfusion, and severe treatment-related rash are urgent. A patient taking immunomodulatory therapy with unilateral leg swelling or sudden breathlessness requires venous-thromboembolism assessment. Red flags override a routine clinic timetable; they should trigger local emergency protocols and direct communication with the treating team.
Indian Clinical Context
India has substantial variation in access to electrophoresis, free-light-chain assays, marrow immunophenotyping, cytogenetics, modern imaging, radiotherapy, dialysis, transplantation and newer medicines. A safe pathway distinguishes the minimum diagnostic dataset from desirable risk refinement. If low-dose whole-body CT, PET-CT or whole-body MRI is unavailable locally, clinicians should refer or choose the best validated alternative without pretending that a less sensitive plain survey is equivalent. Samples may need transport to an accredited laboratory; results must be interpreted with assay-specific ranges, renal function and pre-analytical quality.
Treatment recommendations from current guidelines, EHA-ESMO or IMWG are evidence frameworks, not Indian reimbursement rules. Drug approval, public procurement, insurance coverage and institutional protocols differ, and imported cost-effectiveness decisions cannot be assumed applicable. A less expensive accessible regimen delivered reliably can be safer than an aspirational plan with interrupted supply, but affordability must not be used to conceal options. Patients should receive transparent discussion of goals, expected benefit, toxicity, travel, transfusion and infection-support requirements. Generic availability does not remove teratogenicity, thrombosis or monitoring safeguards.
Referral networks should identify centres capable of renal rescue, radiation, orthopaedic stabilisation, stem-cell collection and complex relapse therapy. Where patients travel far, coordinate blood tests locally, provide a written emergency plan and define who reviews results. Infection prevention must account for local epidemiology without indiscriminate antibiotics. This guide cannot establish a national Indian regimen, dose schedule or transplant threshold; those require current Indian regulatory information, local formulary and specialist judgement. It does establish that renal injury, neurological compromise, hypercalcaemia and sepsis must not wait for financial or administrative completion.
NMC Competency Mapping
This topic integrates undergraduate competencies across pathology, medicine, pharmacology, radiodiagnosis, orthopaedics and palliative care. A learner should explain plasma-cell clonality, monoclonal immunoglobulin production, marrow failure, osteoclast activation, light-chain renal injury and immunoparesis. They should recognise the clinical cluster of persistent skeletal pain, pathological fracture, anaemia, infection, kidney dysfunction and hypercalcaemia while understanding that none is individually specific. The expected diagnostic skill is to construct and interpret a sequence: CBC and film, renal and calcium profile, serum and urine monoclonal studies, free light chains, marrow examination, imaging and risk cytogenetics.
At an applied level, the learner should distinguish MGUS, smouldering myeloma, active multiple myeloma, solitary plasmacytoma, AL amyloidosis and alternative causes of a high globulin or lytic lesion. They should state CRAB and SLiM concepts without inventing thresholds from memory when making a real clinical decision. They should identify cord compression, severe hypercalcaemia, sepsis, pathological fracture, hyperviscosity and rapidly progressive renal impairment as emergencies, initiate safe supportive steps and escalate promptly.
Management competencies include explaining why therapy is combination- and risk-adapted, the role of autologous transplantation, response monitoring and supportive care. Pharmacology links include corticosteroid toxicity, immunomodulatory teratogenicity and thrombosis, proteasome-inhibitor neuropathy, anti-CD38 transfusion interference and bone-agent renal/dental precautions. Communication includes discussing diagnostic uncertainty, incurability with prolonged disease control, clinical trials, costs and palliative needs without removing hope. This mapping is an educational interpretation of the 2024 NMC curriculum, not a claim that NMC mandates a specific modern regimen or examination question.
Key Exam Pearls for NEET PG
Remember the diagnostic logic rather than CRAB alone. Active myeloma requires clonal marrow plasma cells or a plasmacytoma plus an attributable myeloma-defining event. The SLiM biomarkers supplement CRAB because they identify selected patients at very high progression risk before irreversible organ damage; exact thresholds and imaging definitions should be verified from IMWG criteria. A serum M spike can be absent in light-chain or non-secretory disease, so immunofixation and serum free-light-chain testing matter. Renal dysfunction changes free-light-chain interpretation and drug dosing.
Classic laboratory associations include normocytic anaemia, rouleaux, raised total protein with low albumin, renal impairment and hypercalcaemia, but normal values do not exclude early disease. Myeloma bone lesions are lytic, and radionuclide bone scans can be insensitive because osteoblastic activity is limited. Whole-body low-dose CT, PET-CT and MRI answer different questions. A solitary plasmacytoma requires exclusion of systemic disease. MGUS and smouldering myeloma are not treated merely because a clone exists; classification and surveillance prevent both overtreatment and missed progression.
Cast nephropathy is a time-critical consequence of high free-light-chain burden. Avoid nephrotoxins, correct volume and calcium problems, and start effective specialist-directed anti-myeloma treatment promptly. In a patient receiving an anti-CD38 antibody, warn transfusion services because pre-transfusion testing can be affected. Immunomodulatory drugs require pregnancy prevention and thrombosis assessment. Bone-modifying therapy needs dental and renal planning. In an exam vignette, neurological deficit with back pain is cord compression, fever on treatment is an emergency, and severe headache or visual change with a large paraprotein raises hyperviscosity.
Frequently Asked Questions
Does finding a monoclonal protein mean that the patient has active multiple myeloma?
No. A monoclonal protein can occur in MGUS, smouldering myeloma, lymphoplasmacytic disorders, AL amyloidosis and other clonal conditions. Active myeloma requires the complete IMWG diagnostic framework, including clonal confirmation and an attributable CRAB feature or validated myeloma-defining biomarker. Classification should be made from the complete clinical, laboratory, marrow and imaging dataset.
Can normal serum protein electrophoresis safely exclude multiple myeloma?
No. Light-chain and uncommon non-secretory presentations may lack a conspicuous serum M spike. Clinical suspicion should lead to serum immunofixation, serum free-light-chain measurement, appropriate urine studies, marrow assessment and imaging rather than reliance on one normal electrophoresis result. Kidney function and assay-specific reference ranges also affect free-light-chain interpretation.
Why is kidney dysfunction in suspected myeloma treated as time critical?
High circulating free light chains can cause rapidly progressive cast nephropathy, and reversibility may decline with delay. Same-day assessment should address volume, calcium, nephrotoxins, free-light-chain burden and other kidney causes while haematology and nephrology coordinate prompt clone-directed and supportive care.
Is age alone enough to decide that a patient is unsuitable for autologous transplantation?
No. Transplant decisions consider physiological fitness, frailty, organ function, comorbidity, disease biology, patient preference and local programme criteria. Chronological age informs risk but should not be an isolated exclusion or a reason to offer inadequately considered treatment. Assessment should come from an experienced transplant service after appropriate induction planning.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic